checkAd
    Startseite > Aktien > Alzamend Neuro > Nachrichten
    Alzamend Neuro Aktie
    0,5800
     
    USD
    0,00 %
    0,0000 USD
    Letzter Kurs 08.06.24 Nasdaq
    0,5563
     
    USD
    400 STK
    Geldkurs 07.06.24
    0,5869
     
    USD
    100 STK
    Briefkurs 07.06.24
    ISIN: US02262M4078 · WKN: A3EYCP · SYM: ALZN · USA

    Neueste Nachrichten

    Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel
    22.05.24 · Business Wire (engl.) · Alzamend Neuro
    Alzamend Neuro Announces Initial Closing of Private Placement
    14.05.24 · Business Wire (engl.) · Alzamend Neuro
    Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million
    09.05.24 · Business Wire (engl.) · Alzamend Neuro
    Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program
    07.05.24 · Business Wire (engl.) · Alzamend Neuro
    Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients
    11.12.23 · Business Wire (engl.) · Alzamend Neuro
    Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients
    20.11.23 · Business Wire (engl.) · Alzamend Neuro
    Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
    16.11.23 · Business Wire (engl.) · Alzamend Neuro
    Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001
    13.11.23 · Business Wire (engl.) · Alzamend Neuro
    Alzamend Neuro Announces Reverse Stock Split
    30.10.23 · Business Wire (engl.) · Alzamend Neuro
    Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001
    23.10.23 · Business Wire (engl.) · Alzamend Neuro
    Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
    02.10.23 · Business Wire (engl.) · Alzamend Neuro
    Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement
    22.09.23 · Business Wire (engl.) · Alzamend Neuro